Filana Therapeutics (FLNA) Retained Earnings (2010 - 2026)
Filana Therapeutics (FLNA) posted quarterly Retained Earnings of $578.6 million for Q2 2026, up 3.2% year-over-year from $560.7 million in Q2 2025, and up 0.71% quarter-over-quarter from $574.5 million in Q1 2026.
Filana Therapeutics (FLNA) Retained Earnings (2010 - 2026) Analysis & Trends
Filana Therapeutics' Retained Earnings history runs 17 years deep, the most recent figure standing at $578.6 million for Q2 2026.
- In Q2 2026, Retained Earnings rose 3.2% year-over-year to $578.6 million; the TTM figure through Jun 2026 stood at $578.6 million (up 3.2% YoY), while the FY2025 annual figure was $570.4 million, up 3.57% from the prior year.
- Retained Earnings for Q2 2026 stood at $578.6 million, up from $574.5 million in the prior quarter.
- The five-year high for Retained Earnings was $578.6 million in Q2 2026, with the low at $434.3 million in Q1 2024.
- The 5-year median for Retained Earnings is $528.3 million (2023), against an average of $523.9 million.
- The sharpest annual moves came in 2024 and 2025: Retained Earnings dropped 15.14% in 2024, then advanced 28.05% in 2025.
- Filana Therapeutics' Retained Earnings stood at $511.0 million in 2022, then grew by 1.4% to $518.2 million in 2023, then increased by 6.29% to $550.8 million in 2024, then gained by 3.57% to $570.4 million in 2025, then increased by 1.43% to $578.6 million in 2026.
- Business Quant data shows FLNA's Retained Earnings at $578.6 million in Q2 2026, $574.5 million in Q1 2026, and $570.4 million in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 15.69 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 37.62 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 558.00 Mn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 5.10 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 13.05 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | -6.33 Bn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 20.91 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 6.57 Bn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 4.38 Bn |
| 10 | Filana Therapeutics | 46.14 Mn | 46.14 Mn | - | 578.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 578.58 Mn |
| Mar 31, 2026 | 574.51 Mn |
| Dec 31, 2025 | 570.44 Mn |
| Sep 30, 2025 | 565.07 Mn |
| Jun 30, 2025 | 560.66 Mn |
| Mar 31, 2025 | 556.08 Mn |
| Dec 31, 2024 | 550.77 Mn |
| Sep 30, 2024 | 544.11 Mn |
| Jun 30, 2024 | 538.50 Mn |
| Mar 31, 2024 | 434.28 Mn |
| Dec 31, 2023 | 518.20 Mn |
| Sep 30, 2023 | 514.92 Mn |
| Jun 30, 2023 | 513.51 Mn |
| Mar 31, 2023 | 511.79 Mn |
| Dec 31, 2022 | 511.05 Mn |
| Sep 30, 2022 | 463.10 Mn |
| Jun 30, 2022 | 462.49 Mn |
| Mar 31, 2022 | 461.89 Mn |
| Dec 31, 2021 | 461.18 Mn |
| Sep 30, 2021 | 460.66 Mn |